HRP20241581T1 - Fuzionirani prstenasti spojevi - Google Patents
Fuzionirani prstenasti spojevi Download PDFInfo
- Publication number
- HRP20241581T1 HRP20241581T1 HRP20241581TT HRP20241581T HRP20241581T1 HR P20241581 T1 HRP20241581 T1 HR P20241581T1 HR P20241581T T HRP20241581T T HR P20241581TT HR P20241581 T HRP20241581 T HR P20241581T HR P20241581 T1 HRP20241581 T1 HR P20241581T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- cancer
- image
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 16
- 238000000034 method Methods 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 101710113436 GTPase KRas Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102200006538 rs121913530 Human genes 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010073360 Appendix cancer Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018114788 | 2018-11-09 | ||
| EP19842848.4A EP3735299B1 (en) | 2018-11-09 | 2019-11-08 | Fused ring compounds |
| PCT/US2019/060578 WO2020097537A2 (en) | 2018-11-09 | 2019-11-08 | Fused ring compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241581T1 true HRP20241581T1 (hr) | 2025-01-31 |
Family
ID=69232886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241581TT HRP20241581T1 (hr) | 2018-11-09 | 2019-11-08 | Fuzionirani prstenasti spojevi |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11236068B2 (https=) |
| EP (2) | EP3735299B1 (https=) |
| JP (4) | JP6941241B2 (https=) |
| KR (3) | KR20250012188A (https=) |
| CN (5) | CN112105419B (https=) |
| AR (1) | AR117194A1 (https=) |
| AU (3) | AU2019377130B2 (https=) |
| BR (1) | BR112021008986A2 (https=) |
| CA (1) | CA3087089C (https=) |
| CL (2) | CL2021001171A1 (https=) |
| CO (1) | CO2021005987A2 (https=) |
| CR (1) | CR20210229A (https=) |
| DK (1) | DK3735299T3 (https=) |
| ES (1) | ES3004042T3 (https=) |
| FI (1) | FI3735299T3 (https=) |
| HR (1) | HRP20241581T1 (https=) |
| HU (1) | HUE069365T2 (https=) |
| IL (3) | IL282916B2 (https=) |
| LT (1) | LT3735299T (https=) |
| MA (1) | MA51530B1 (https=) |
| MX (5) | MX2021005428A (https=) |
| MY (1) | MY196726A (https=) |
| PE (2) | PE20260440A1 (https=) |
| PH (1) | PH12021551065A1 (https=) |
| PL (1) | PL3735299T3 (https=) |
| PT (1) | PT3735299T (https=) |
| RS (1) | RS66280B1 (https=) |
| SG (1) | SG11202103298QA (https=) |
| SI (1) | SI3735299T1 (https=) |
| SM (1) | SMT202400487T1 (https=) |
| TW (2) | TWI784209B (https=) |
| UA (1) | UA127930C2 (https=) |
| WO (1) | WO2020097537A2 (https=) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| CN114437065A (zh) | 2019-05-21 | 2022-05-06 | 益方生物科技(上海)股份有限公司 | 杂环化合物，其制备方法和用途 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| IL300309B2 (en) * | 2020-08-12 | 2026-03-01 | Genentech Inc | Synthesis of quinazoline compounds |
| TW202220994A (zh) * | 2020-08-17 | 2022-06-01 | 大陸商貝達藥業股份有限公司 | 雙環化合物，包含其的藥物組合物及其用途 |
| CA3191279A1 (en) | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
| WO2022068921A1 (zh) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| WO2022098625A1 (en) * | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| TWI886356B (zh) * | 2020-11-13 | 2025-06-11 | 美商建南德克公司 | 用於治療實性瘤之方法與包含ｋｒａｓｇ１２ｃ抑制劑及ｖｅｇｆ抑制劑之組成物 |
| EP4243827A1 (en) * | 2020-11-13 | 2023-09-20 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| CN116490508A (zh) * | 2020-11-20 | 2023-07-25 | 北京加科思新药研发有限公司 | Kras g12d抑制剂 |
| CA3204191A1 (en) * | 2020-12-08 | 2022-06-16 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CA3203080A1 (en) * | 2020-12-22 | 2022-06-30 | Hongqi Tian | Preparation and application method of heterocyclic compound as kras inhibitor |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| EP4291199A4 (en) * | 2021-02-09 | 2025-06-18 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2022171013A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 四氢喹唑啉类化合物 |
| WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| CA3210167A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| BR112023016299A2 (pt) * | 2021-02-16 | 2023-11-28 | L Livermore Nat Security Llc | Composições e métodos para inibir kras |
| US20250255868A1 (en) * | 2021-04-09 | 2025-08-14 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound acting as kras g12d inhibitor |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| EP4322954A4 (en) * | 2021-04-16 | 2025-01-29 | Merck Sharp & Dohme LLC | SMALL MOLECULAR INHIBITORS OF THE KRAS G12D MUTANT |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| JP2024516450A (ja) * | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| JP2024519845A (ja) * | 2021-05-19 | 2024-05-21 | ジェネンテック， インコーポレイテッド | 併用療法 |
| US20240300980A1 (en) * | 2021-05-22 | 2024-09-12 | Shanghai Kechow Pharma, Inc. | Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment |
| US20240261444A1 (en) * | 2021-05-26 | 2024-08-08 | Cornell University | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer |
| IL310291A (en) | 2021-07-23 | 2024-03-01 | Theras Inc | Compositions and methods for inhibition of ras |
| CN117858878A (zh) * | 2021-08-18 | 2024-04-09 | 北京加科思新药研发有限公司 | N-环丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| US12110276B2 (en) | 2021-11-24 | 2024-10-08 | Genentech, Inc. | Pyrazolo compounds and methods of use thereof |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| TW202340202A (zh) | 2021-12-22 | 2023-10-16 | 美國加利福尼亞大學董事會 | Gtp酶抑制劑及其用途 |
| AR128211A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| AR128212A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| JP2025505655A (ja) * | 2022-02-07 | 2025-02-28 | ジェネンテック， インコーポレイテッド | １－（（ｓ）－４－（（ｒ）－７－（６－アミノ－４－メチル－３－（トリフルオロメチル）ピリジン－２－イル）－６－クロロ－８－フルオロ－２－（（（ｓ）－１－メチルピロリジン－２－イル）メトキシ）キナゾリン－４－イル）－３－メチルピペラジン－１－イル）プロパ－２－エン－１－オンの固体形態 |
| US12071422B2 (en) * | 2022-02-07 | 2024-08-27 | Genentech, Inc. | Process for synthesis of quinazoline compounds |
| AU2023231139A1 (en) | 2022-03-11 | 2024-09-05 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4473970A4 (en) | 2022-03-31 | 2026-01-21 | Eisai R&D Man Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS |
| US12383557B2 (en) | 2022-04-06 | 2025-08-12 | Genentech, Inc. | Treatment of cancer using combination therapies comprising GDC-6036 and GDC-0077 |
| CR20240508A (es) | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| CN115043729B (zh) * | 2022-07-04 | 2024-09-27 | 青岛大学 | 一种2,2’-二氟联芳基化合物的不对称合成方法 |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| JP2025526744A (ja) | 2022-08-11 | 2025-08-15 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| EP4573095A1 (en) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| CN117085515A (zh) * | 2023-01-15 | 2023-11-21 | 安徽科博瑞环境科技有限公司 | 低表面能抗污染中空纤维膜的制备装置 |
| WO2024153119A1 (en) * | 2023-01-18 | 2024-07-25 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| EP4655298A1 (en) * | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| CN116396202A (zh) * | 2023-04-17 | 2023-07-07 | 南京优氟医药科技有限公司 | 一种（2s，4s）-4-氟代吡咯烷-2-羧酸的制备方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| US20250000802A1 (en) | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
| WO2025010415A1 (en) * | 2023-07-05 | 2025-01-09 | The Regents Of The University Of California | Gtpase inhibitors and uses thereof |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002557A1 (en) | 1997-07-11 | 1999-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V | Novel pharmaceutically active compounds interacting with gtp-binding proteins |
| CN102131389A (zh) | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | 三唑并吡啶jak抑制剂化合物和方法 |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| EP3055290B1 (en) * | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| CN111511729A (zh) | 2017-12-19 | 2020-08-07 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
-
2019
- 2019-11-08 PE PE2025003077A patent/PE20260440A1/es unknown
- 2019-11-08 PT PT198428484T patent/PT3735299T/pt unknown
- 2019-11-08 US US16/679,104 patent/US11236068B2/en active Active
- 2019-11-08 HR HRP20241581TT patent/HRP20241581T1/hr unknown
- 2019-11-08 TW TW108140719A patent/TWI784209B/zh active
- 2019-11-08 SG SG11202103298QA patent/SG11202103298QA/en unknown
- 2019-11-08 RS RS20241331A patent/RS66280B1/sr unknown
- 2019-11-08 MA MA51530A patent/MA51530B1/fr unknown
- 2019-11-08 SM SM20240487T patent/SMT202400487T1/it unknown
- 2019-11-08 CN CN201980026181.6A patent/CN112105419B/zh active Active
- 2019-11-08 UA UAA202101478A patent/UA127930C2/uk unknown
- 2019-11-08 ES ES19842848T patent/ES3004042T3/es active Active
- 2019-11-08 JP JP2020542808A patent/JP6941241B2/ja active Active
- 2019-11-08 CN CN202410280943.8A patent/CN118084867A/zh active Pending
- 2019-11-08 IL IL282916A patent/IL282916B2/en unknown
- 2019-11-08 KR KR1020257000144A patent/KR20250012188A/ko active Pending
- 2019-11-08 HU HUE19842848A patent/HUE069365T2/hu unknown
- 2019-11-08 CN CN202410280860.9A patent/CN118084866A/zh active Pending
- 2019-11-08 SI SI201930862T patent/SI3735299T1/sl unknown
- 2019-11-08 EP EP19842848.4A patent/EP3735299B1/en active Active
- 2019-11-08 EP EP24198360.0A patent/EP4483881A3/en active Pending
- 2019-11-08 CN CN202410281112.2A patent/CN118084868A/zh active Pending
- 2019-11-08 TW TW111140273A patent/TWI883352B/zh active
- 2019-11-08 PE PE2021000682A patent/PE20211504A1/es unknown
- 2019-11-08 BR BR112021008986-1A patent/BR112021008986A2/pt unknown
- 2019-11-08 DK DK19842848.4T patent/DK3735299T3/da active
- 2019-11-08 FI FIEP19842848.4T patent/FI3735299T3/fi active
- 2019-11-08 KR KR1020237033977A patent/KR102751492B1/ko active Active
- 2019-11-08 AR ARP190103302A patent/AR117194A1/es unknown
- 2019-11-08 CA CA3087089A patent/CA3087089C/en active Active
- 2019-11-08 WO PCT/US2019/060578 patent/WO2020097537A2/en not_active Ceased
- 2019-11-08 IL IL311187A patent/IL311187B2/en unknown
- 2019-11-08 MY MYPI2021002582A patent/MY196726A/en unknown
- 2019-11-08 PL PL19842848.4T patent/PL3735299T3/pl unknown
- 2019-11-08 AU AU2019377130A patent/AU2019377130B2/en active Active
- 2019-11-08 CN CN202410281087.8A patent/CN118084870A/zh active Pending
- 2019-11-08 MX MX2021005428A patent/MX2021005428A/es unknown
- 2019-11-08 CR CR20210229A patent/CR20210229A/es unknown
- 2019-11-08 LT LTEPPCT/US2019/060578T patent/LT3735299T/lt unknown
- 2019-11-08 KR KR1020207024122A patent/KR102587544B1/ko active Active
-
2021
- 2021-05-04 CL CL2021001171A patent/CL2021001171A1/es unknown
- 2021-05-07 PH PH12021551065A patent/PH12021551065A1/en unknown
- 2021-05-07 MX MX2025002975A patent/MX2025002975A/es unknown
- 2021-05-07 MX MX2025002979A patent/MX2025002979A/es unknown
- 2021-05-07 MX MX2024008118A patent/MX2024008118A/es unknown
- 2021-05-07 CO CONC2021/0005987A patent/CO2021005987A2/es unknown
- 2021-05-07 MX MX2025002980A patent/MX2025002980A/es unknown
- 2021-07-15 JP JP2021116809A patent/JP7374960B2/ja active Active
- 2021-12-17 US US17/644,993 patent/US12084429B2/en active Active
-
2022
- 2022-03-01 AU AU2022201413A patent/AU2022201413B9/en active Active
- 2022-03-22 CL CL2022000698A patent/CL2022000698A1/es unknown
-
2023
- 2023-10-25 JP JP2023183500A patent/JP7579414B2/ja active Active
-
2024
- 2024-02-13 AU AU2024200904A patent/AU2024200904B2/en active Active
- 2024-06-18 US US18/747,054 patent/US20250059163A1/en active Pending
- 2024-10-25 JP JP2024187827A patent/JP2025026853A/ja active Pending
-
2025
- 2025-10-20 IL IL324078A patent/IL324078A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241581T1 (hr) | Fuzionirani prstenasti spojevi | |
| JP2021521194A5 (https=) | ||
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| JP5947307B2 (ja) | Ｋｃｎｑ２／３調節因子としての置換６−アミノ−ニコチンアミド | |
| RU2017131430A (ru) | Способ лечения рака, ассоциированного с мутацией ras | |
| MX384828B (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| US20150087673A1 (en) | Methods for using and biomarkers for ampk-activating compounds | |
| JP2018507249A5 (https=) | ||
| PH12019501979A1 (en) | Anti-rsv monoclonal antibody formulation | |
| MA41038A (fr) | Composés d'aminopyridyloxypyrazole | |
| Li et al. | Macrophages-stimulated PRMT1-mediated EZH2 methylation promotes breast cancer metastasis | |
| WO2013112950A3 (en) | Certain chemical entities, compositions, and methods | |
| MX369683B (es) | Composición para la reducción del encrespado del cabello. | |
| WO2017062496A3 (en) | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer | |
| DK1631312T3 (da) | Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom | |
| Lippolis et al. | Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1 | |
| PH12022550441A1 (en) | Azaheteroaryl compound and application thereof | |
| HRP20201791T1 (hr) | Postupci za liječenje raka sa hemizigotnim gubitkom gena tp53 | |
| JOP20170108A1 (ar) | مثبطات معزز نظير zeste 2 | |
| EA202191658A1 (ru) | Антитела против фактора c2b комплемента человека и способы применения | |
| Ji et al. | Serum from chronic hepatitis B patients promotes growth and proliferation via the IGF-II/IGF-IR/MEK/ERK signaling pathway in hepatocellular carcinoma cells | |
| Chen et al. | A direct interaction between P53-binding protein 1 and minichromosome maintenance complex in Hepg2 cells | |
| WO2009061130A3 (en) | Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same | |
| Han et al. | TRAIP regulates Histone H2B monoubiquitination in DNA damage response pathways | |
| EP4328325A4 (en) | Composition, kit, and application for detection of colorectal cancer |